Jan 1, 2026, 2:57 AM EST - 7 hours ago
Merck is rated a buy, with strong earnings growth, rising cash flow, and balance sheet strength supporting a bullish outlook. Keytruda's double-digit growth and margin expansion drive MRK's profits, b...
MRK
GOOGL
Z
ZG
OIH
PXJ
UCO